Heart Disease

Information, Symptoms, Treatments and Resources


Fish Oil Capsules and Supplementation for Heart Disease: The Benefits and Side Effects



1. Psota TL, Gebauer SK, Kris-Etherton P. Dietary omega-3 fatty acid intake and cardiovascular risk. Am J Cardiol. 2006;98:3i-18i.

2. Jacobson TA. Secondary prevention of coronary artery disease with omega-3 fatty acids. Am J Cardiol. 2006;98:61i-70i.

3. Weitz D, Weintraub H, Fisher E, Schwartzbard AZ. Fish oil for the treatment of cardiovascular disease. Cardiol Rev. 2010;18:258-63.

4. Dimitrow PP, Jawien M. Pleiotropic, Cardioprotective Effects of Omega-3 Polyunsaturated Fatty Acids. Mini Rev Med Chem. 2009.

5. Leaf A. On the reanalysis of the GISSI-Prevenzione. Circulation. 2002;105:1874-5.

6. Lee JH, O’Keefe JH, Lavie CJ, Harris WS. Omega-3 fatty acids: cardiovascular benefits, sources and sustainability. Nature reviews. Cardiology. 2009;6:753-8.

7. Lavie CJ, Milani RV, Mehra MR, Ventura HO. Omega-3 polyunsaturated fatty acids and cardiovascular diseases. Journal of the American College of Cardiology. 2009;54:585-94.

8. Eckel RH. The fish oil story remains fishy. Circulation. 2010;122:2110-2.

9. Marchioli R, Schweiger C, Tavazzi L, Valagussa F. Efficacy of n-3 polyunsaturated fatty acids after myocardial infarction: results of GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico. Lipids. 2001;36 Suppl:S119-26.

10. Roth EM, Harris WS. Fish oil for primary and secondary prevention of coronary heart disease. Curr Atheroscler Rep. 2010;12:66-72.

11. Lavie CJ, Milani RV, Mehra MR, Ventura HO. Omega-3 polyunsaturated fatty acids and cardiovascular diseases. J Am Coll Cardiol. 2009;54:585-94.

12. McGowan MP, Proulx S. Nutritional supplements and serum lipids: does anything work? Current atherosclerosis reports. 2009;11:470-6.

13. Robinson JG, Stone NJ. Antiatherosclerotic and antithrombotic effects of omega-3 fatty acids. Am J Cardiol. 2006;98:39i-49i.

14. Omega-3 polyunsaturated fatty acids (Omacor) for hypertriglyceridemia. Med Lett Drugs Ther. 2005;47:91.

15. Nambi V, Ballantyne CM. Combination therapy with statins and omega-3 fatty acids. Am J Cardiol. 2006;98:34i-38i.

16. Rupp H. Omacor (prescription omega-3-acid ethyl esters 90): From severe rhythm disorders to hypertriglyceridemia. Adv Ther. 2009;26:675-90.

17. Stalenhoef AF, de Graaf J, Wittekoek ME, Bredie SJ, Demacker PN, Kastelein JJ. The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertriglyceridemia. Atherosclerosis. 2000;153:129-38.

18. Saravanan P, Davidson NC, Schmidt EB, Calder PC. Cardiovascular effects of marine omega-3 fatty acids. Lancet. 2010;376:540-50.

19. Zampelas A. Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability. Atherosclerosis. 2010;212:34-5.

20. Bays H. Clinical overview of Omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids. Am J Cardiol. 2006;98:71i-76i.

21. Kar S, Chockalingam A. Statin-Associated Rhabdomyolysis With Acute Renal Failure Complicated by Intradialytic NSTEMI: A Review of Lipid Management Considerations. Am J Ther. 2010.

22. Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday RM, Sweetnam PM, Elwood PC, Deadman NM. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet. 1989;2:757-61.

23. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369:1090-8.

24. Harper CR, Jacobson TA. Usefulness of omega-3 fatty acids and the prevention of coronary heart disease. Am J Cardiol. 2005;96:1521-9.

25. Rauch B, Schiele R, Schneider S, Diller F, Victor N, Gohlke H, Gottwik M, Steinbeck G, Del Castillo U, Sack R, Worth H, Katus H, Spitzer W, Sabin G, Senges J. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation. 2010;122:2152-9.

26. Galan P, Kesse-Guyot E, Czernichow S, Briancon S, Blacher J, Hercberg S. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ. 2010;341:c6273.

27. Kromhout D, Giltay EJ, Geleijnse JM. n-3 fatty acids and cardiovascular events after myocardial infarction. The New England journal of medicine. 2010;363:2015-26.



None reported. 

Explore More In Our Hep C Learning Center
image description
What Is Hepatitis C?
Learn about this treatable virus.
image description
Diagnosing Hepatitis C
Getting tested for this viral infection.
image description
Just Diagnosed? Here’s What’s Next
3 key steps to getting on treatment.
image description
Understanding Hepatitis C Treatment
4 steps to getting on therapy.
image description
Your Guide to Hep C Treatments
What you need to know about Hep C drugs.
image description
Managing Side Effects of Treatment
How the drugs might affect you.
image description
Making Hep C Treatment a Success
These tips may up your chances of a cure.